June 15, 2016
3 min watch
Save

VIDEO: Rituximab does not increase malignancy rates in patients with rheumatoid arthritis

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

LONDON — At the EULAR Annual Congress, Matthew D. Cascino, MD, discussed a study which found patients with rheumatoid arthritis treated with rituximab did not have increased malignancy rates.